Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 and Lapatinib in Trastuzumab-resistant HER2+ Breast Cancer
NCT01589861Phase 2Terminated
- Sponsor
- Institut Paoli-Calmettes
- Start
- Dec 2011
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buparlisib in breast cancer, sponsored by Institut Paoli-Calmettes. Primary endpoints: Maximum Tolerated Dose at 28 days and Objective Response Rate up to 1 year. Started Dec 2011; status: terminated.
02
Drugs
buparlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01589861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01589861.